A new five-year study of nearly 1,600 patients finds that genetic testing can help determine the safest dose of the blood thinner warfarin, with fewer side effects, in patients undergoing joint replacement surgery.
Click to zoom
New study finds that genetic testing helps determine safest dose of blood thinner with fewer side effects in patients undergoing joint replacement surgery.
The day may come when patients go to the doctor, have their blood pressure taken, and then a cheek swab is used to genotype their whole genome.”
— Scott Woller, MD, Intermountain Medical Center
SALT LAKE CITY, UT, USA , October 23, 2017 /EINPresswire.com/ -- A new five-year study of nearly 1,600 patients finds that genetic testing can help determine the safest dose of the blood thinner warfarin, with fewer side effects, in patients undergoing joint replacement surgery.
Researchers in the national study, which included clinicians from Intermountain Healthcare, found that when doctors dose according to a patient’s genetic makeup when prescribing warfarin, a blood thinner commonly prescribed to prevent life-threatening blood clots, the numbers of adverse side effects like hemorrhage are significantly decreased.
Warfarin is a commonly prescribed, very effective anticlotting medicine — but it’s often associated with adverse complications and each patient requires a different dosage to achieve the desired treatment effect.
That unique dosing is based in part on an individual’s genetics, and great interest exists in understanding whether an individual’s genetics can guide how to best prescribe warfarin to reach the optimal therapeutic range.
The five-year study among patients having an elective hip or knee replacement was coordinated at Washington University in St. Louis, and was performed at Intermountain Medical Center, Hospital for Special Surgery in New York, Washington University, University of Utah, Rush University Medical Center and the University of Texas Southwestern.
Researchers say study findings from the GIFT study (Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis) are significant. Compared to patients who received a standard dose, patients who received genetically-dosed warfarin had a 27 percent reduction in complications.
Specifically, their major bleeding was reduced by 75 percent, the incidence of excessive international normalized ratios was reduced by about 30 percent, and blood clots occurred 15 percent less often. No patients died during the study.
“In 2017, what I think GIFT shows us is that when we give warfarin based on an individual’s genes, we can reduce their risk for adverse outcomes compared to using a standardized approach,” Dr. Woller said. “What’s uncertain now is how that observation can be pragmatically adopted clinically to provide cost-effective care.”
The findings from the GIFT study are published in the Journal of the American Medical Association, and could be used immediately. Since 2007, the Food and Drug Administration has included language in its warfarin packaging that encourages the use of genetic guidance, if it’s available.
“Differences can be identified by looking at a patient’s genetic makeup, and specifically at the genes that are responsible for the liver’s metabolism of the drug,” said Scott Woller, MD, co-director of the Thrombosis Program at Intermountain Medical Center and principal investigator for Intermountain Healthcare.
Researchers studied nearly 1,600 individuals age 65 and older undergoing an elective hip or knee replacement surgery. They found that tailoring the warfarin dosage to fit the individual’s genome resulted in reductions in four negative outcomes: Occurrence of a blood clot, major bleeding, an international normalized ratio reading greater than 4, and death. The international normalized ratio is the laboratory test used to assess warfarin’s effect, and the desirable range for patients after hip or knee replacement is 2-3.
Patients in the trial were randomly assigned to one of two groups. One group received warfarin dosing based on standard factors such as age, height, and weight. The second group was dosed based on these clinical factors, plus genetic variants.
Previous studies have shown how the various genetic differences, called polymorphisms, affect the metabolism of warfarin, Dr. Woller said.
He noted that Brian F. Gage, MD, MSc, of Washington University, principal investigator for the entire GIFT study, played a significant role with other researchers in creating an algorithm that uses an individual’s genetics to prescribe a more precise personalized dose of warfarin. The algorithm weighs individual patient characteristics, such as gender, weight, age and race, as well as one’s genetics.
Dr. Woller said it’s important to understand that the dose that will put a patient in the 2-3 international normalized ratio therapeutic range can vary greatly: Some patients require just 0.5 mg of warfarin a day, while others might require 15 to 20 mg a day.
“If we can identify the person who requires 0.5 mg, we’ll start by giving them a low dose and it’s less likely we’ll overshoot,” he said. “Likewise for the patient who requires 20 mg, we’ll avoid lower dosing initially. Rather, we’d start by giving them significantly more because we know their stable warfarin dose will be higher.”
“The challenge has always been cost-effectiveness, because you need to do genotyping on an individual and historically that hasn’t been cheap,” said Dr. Woller. “The day may come when patients go to the doctor, have their blood pressure taken, and then a cheek swab is used to genotype their whole genome. The information would be available in the future, if they needed warfarin to protect against blood clots or to guide the dosing of antibiotics dependent on genetics for metabolism, for example, or to assess personal risk for breast cancer.”
=============================
A recent study by Pew concludes that over 58% of Americans believe racism is a “big problem” in society. H. Richard Milner, a noted researcher and expert on race and education at the University of Pittsburgh says that, “education is the key to addressing inequity and racism in society,” and if we are not, “working in education to combat racism, we are complicit in maintaining inequity and the status quo.” Are educators prepared and willing to take this on? C.M. Rubin (Founder of CMRubinWorld) opened up the conversation on racism and the role of education with Millennials around the globe.
Harmony Siganporia notes, “Any nation that can stomach the principle of caste, which is the most brutal ‘classification’ of human beings based on birth anywhere in the world, cannot help but differentiate, and differentiate repeatedly, on the basis of every parameter society can construct in a desperate and insular bid to separate ‘us’ from ‘them.’” Dominique Dryding believes that until educational institutions, “take the lived experiences of their student bodies seriously and recognize that racism does not only include name calling and physical exclusion, racism in schools and universities will not end.” Guest blogger Salathia Carr writes, “Judgment is very easy to make when you’re not living that way. But, if we force discussions about inequality from the very first history class we take, you cannot avoid it.”
Read the full article here
The Millennial Bloggers are based all over the world. They are innovators in entrepreneurship, journalism, education, entertainment, health and wellbeing and academic scholarship. They are Alusine Barrie, Sajia Darwish, James Kernochan, Kamna Kathuria, Jacob Deleon Navarrete, Reetta Heiskanen, Shay Wright, Isadora Baum, Wilson Carter III, Francisco Hernandez, Erin Farley, Dominique Alyssa Dryding, Harry Glass, Harmony Siganporia and Bonnie Chiu.
The mission of CMRubinWorld is to ask the important questions, share the most innovative ideas and ultimately be a bridge builder between the past and the future of learning.
CMRubinWorld launched in 2010 to explore what kind of education would prepare students to succeed in a rapidly changing globalized world. Its award winning series, The Global Search for Education, is a highly regarded trailblazer in the renaissance of 21st century education, and occupies a widely respected place in the pulse of key issues facing every nation and the collective future of all children. It connects today’s top thought leaders with a diverse global audience of parents, students and educators. Its highly readable platform allows for discourse concerning our highest ideals and the sustainable solutions we must engineer to achieve them. C. M. Rubin has produced hundreds of interviews and articles discussing an extensive array of topics under a singular vision: when it comes to the world of children, there is always more work to be done.
For more information on CMRubinWorld
==========================
